Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose pharmacokinetics of KSP-1007 in healthy adult Chinese subjects
jRCT2071230099Phase 1Completed
- Sponsor
- Sumitomo Pharma
- Start
- Dec 2023
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of KSP-1007 in hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) (4 arms), sponsored by Sumitomo Pharma. Primary endpoint: Pharmacokinetic parameters of KSP-1007. Started Dec 2023; status: completed.
02
Drugs
KSP-1007
03
Conditions
hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on jRCT2071230099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071230099.